Abstract We report two cases of gastric cancer with peritoneal carcinomatosis successfully responding to combination chemotherapy of S-1 and cisplatin, leading to a clinical complete response (cCR). In case 1, a 60-year-old woman achieved a cCR after 6 cycles of S-1 and cisplatin. Eight cycles of S-1 and cisplatin and 16 cycles of S-1 alone were administered. Since treatment with S-1 alone, only observation has been performed with no recurrence. In case 2, a 63-year-old man achieved cCR after 2 cycles of S-1 and cisplatin chemotherapy. After 8 cycles of chemotherapy, cCR was confirmed, and a curative operation was performed. After surgery, a small number of viable cells were found in the pathological examination. Fifty-four reports of cCR cases of advanced non-resectable or metastatic gastric cancer with chemotherapy have been published, but none mentioned the treatment options after cCR. In this report, we show two patients choosing different paths after achieving cCR by chemotherapy. In our surgical case, residues of pathologically viable cancer cells were confirmed, so surgery might be recommended after cCR, but further investigation will be needed.
Introduction
Gastric cancer is the most common neoplasm in Japan. Systemic chemotherapy with 1 M tegafur/0.4 M gimestat/ 1 M ostat potassium (S-1) and cisplatin (CDDP) is recommended for inoperable or recurrent advanced gastric cancer as the first-line chemotherapy in the Japanese guideline [1] . S-1 is an oral fluoropyrimidine anticancer drug developed in Japan and contains gimeracil, which inhibits 5-fluorouracil (5-FU) degradation, and oteracil, which reduces the gastrointestinal toxicity of 5-FU. A phase III trial of S-1 and CDDP, named the SPIRIT trial, showed prolonged overall survival of 13 months [2] . In this study, the overall response rate was 54 %; however, only one of 87 patients administered S-1 and CDDP achieved a clinical complete response (cCR). Here, we report two cases of gastric cancer with peritoneal carcinomatosis that successfully responded to S-1 and CDDP, leading to cCR. After achieving cCR, the two cases were followed by different procedures: (1) observation and (2) operation at the patient's request.
Case 1
A 60-year-old woman with no cancer-related past or family history visited a hospital with abdominal pain. No marked physical and laboratory findings were found. Gastrointestinal endoscopic fiberoscopy (GIF) was carried out and Borrmann type 3 advanced gastric carcinoma was found on the anterior wall of the stomach body (Fig. 1a) . Computed tomography (CT) was carried out and regional lymph node metastases, peritoneal dissemination, and malignant ascitic fluid were suspected (Fig. 1b) . Exploratory laparotomy was performed and peritoneal dissemination nodules were revealed. Pathological examination of the dissemination nodules led to the diagnosis of poorly differentiated tubular adenocarcinoma and signet-ring cell carcinoma. Because of peritoneal carcinomatosa, it was impossible to perform a curative operation, and the patient was referred to our institute. At our hospital, systemic chemotherapy consisting of S-1 and CDDP was started: 40 mg/m 2 (50 mg/body) of S-1 was given orally twice daily on day 1-21, and 60 mg/m 2 (85 mg/body) of CDDP was infused on day 8, every 35 days. CT was carried out after two cycles of this regimen and showed the disappearance of the disseminated nodules and metastatic lymph nodes, and ascitic fluid was decreased. CT after six cycles showed that ascites had also disappeared (Fig. 1d) . GIF (Fig. 1c) and positron emission tomography/CT (PET/CT) found no malignant signs, and thus the objective response was evaluated as cCR according to RECIST criteria (Response Evaluation Criteria in Solid Tumors), because a complete pathological examination was not done. Tumor markers were within normal limits. Overall, eight cycles of S-1 and CDDP were administered, but the dosage of CDDP was reduced to 70 mg/body in cycles 6 and 7, and 60 mg/body in cycle 8 because of grade 4 neutropenia in cycle 6 and 7 and grade 3 in cycle 8 (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.0). After eight cycles of S-1 and CDDP, S-1 alone was administered for 42 months at the patient's request without grade 4 hematological adverse effects and grade 3 and 4 non-hematologic adverse effects. We suggested surgery, but it was rejected. After treatment with S-1 alone, only observation has been performed with no recurrence.
Case 2
A 63-year-old man with no cancer-related past or family history visited a hospital because of abdominal pain. No marked physical and laboratory findings were found. GIF was carried out and Borrmann type 3 advanced gastric cancer was found on the greater curvature of the lower stomach body (Fig. 2a) . CT was carried out and regional lymph node metastases, marked ascites, and peritoneal dissemination were noted (Fig. 2b) . Pathological examination of biopsy specimens from GIF led to the diagnosis of poorly differentiated tubular adenocarcinoma without HER2-neu overexpression. Because of marked ascites and peritoneal dissemination, it was impossible to perform a curative operation, and systemic chemotherapy with S-1/ CDDP was started using the same regimen as for case 1. The dosages of S-1 and CDDP were 120 mg/body/day and 100 mg/body on day 8. CT was carried out after two cycles of this regimen and showed the disappearance of metastatic lymph nodes, ascites, and peritoneal dissemination. CT examinations were carried out after every two cycles, and cCR was confirmed according to RECIST criteria. Eight cycles of S-1 and CDDP were performed; grade 3 anemia and grade 1 renal dysfunction were observed in cycle 5 and the dosage of CDDP was reduced to 90 mg/body in cycles 6, 7, and 8. No other adverse effects were observed. CT (Fig. 2d) , PET/CT, and the pathological examination of biopsy specimens from GIF (Fig. 2c ) also confirmed cCR. We suggested surgery, the patient agreed, and distal gastrectomy and regional lymph node dissection were performed immediately. Viable cancer cells were not confirmed in the removed lymph nodes and peritoneal cavity, microscopically, and the therapeutic effect grade was 2 because viable cells in the stomach where the tumor was first found were within one-third and most of the nuclei had broken down. After the operation, adjuvant chemotherapy with S-1 alone was administered and, at present, no recurrence has been observed for 8 months.
Discussion
The National Comprehensive Cancer Network (NCCN) guideline showed that the definitive first-line chemotherapy for metastatic or locally advanced cancer without the indication of chemoradiation is trastuzumab with CDDP and fluoropyrimidine for HER2-neu overexpression-positive cases. It recommends DCF (docetaxel, cisplatin, and 5-FU), ECF (epirubicin, cisplatin, and 5-FU), ECF modulations, and FP (5-FU or capecitabine, and cisplatin) for HER2-neu overexpression-negative cases [3] . On the other hand, the Japanese guideline shows that S-1 and CDDP are regarded as having the best prognosis as first-line chemotherapy on the basis of two phase III studies, JCOG9912 [4] and SPRITS trials [2] . JCOG9912 showed that S-1 is non-inferior to 5-FU in overall survival for non-resectable or recurrent advanced gastric cancer. SPIRITS showed that S-1 and CDDP is superior to S-1 alone in overall survival. Our two patients were treated with S-1 and CDDP according to the Japanese gastric cancer treatment guideline, and cCR was achieved.
The SPRITS trial showed only one case of cCR [2] ; however, detailed data were not shown. Fifty-four reports of cCR cases of advanced non-resectable or metastatic gastric cancer with oral or intravenous anticancer drugs were identified through the PubMed system and other related websites (Table 1) . Treatment is included in 45 reports; 35 of 45 cases (77.8 %) continued chemotherapy and 3 of 27 recurred during continued chemotherapy. Seven of 45 cases stopped chemotherapy after achieving cCR on evaluation and one recurrence was reported. The durations of cCR are shown in 49 case reports and the range of durations is 2-90 months and the median is 17 months. Three of 45 patients (6.5 %) had undergone operations and two showed a pathological complete response, but in the other, viable cancer cells were proven pathologically.
Treatment after cCR evaluation has not been discussed, and there is no consensus. No previously published case reports about cCR compared the treatment options. In this report, we show two patients choosing different paths after achieving cCR by chemotherapy. Of our two patients, one wished to undergo surgery and the other wanted to be observed. It is unknown which decision is correct; however, it is thought that the decision to observe should be made after careful consideration, because recurrence or residues of pathological viable cancer cells have been seen to some degree. More investigation is warranted to answer this clinical question. l-OHP oxaliplatin, TXL paclitaxel, MMC mitomycin C, UFT tegaer/uracil, DXR doxorubicin, CPT-11 irinotecan hydrochloride, GEM gemcitabine, DOC docetaxel, 5 0 -DFUR 5 0 -doxifluridine, UFT-E enteric tegaer/uracil
